Angiotensin converting enzyme 2 activator (DIZE) modulates metabolic profiles in mice, decreasing lipogenesis

Protein and Peptide Letters

Volumn 22, Issue 4, 2015, Pages 332-340

  De Macêdo, Simone Moreira ^a   Guimarãres, Talita Antunes ^a   Andrade, João Marcus Oliveira ^a   Guimarães, André Luiz Sena ^a   De Paula, Alfredo Maurício Batista ^a   Ferreira, Anderson José ^b   Santos, Sérgio Henrique Sousa ^a,b  

^a STATE UNIVERSITY OF MONTES CLAROS   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

ACE 2; Adipose tissue; Angiotensin II; Diminazene aceturate; Lipolysis; Metabolic disorder

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSINOGEN; CHOLESTEROL; DIMINAZENE ACETURATE; DIPEPTIDYL CARBOXYPEPTIDASE; FATTY ACID SYNTHASE; GLUCOSE; INSULIN; PLACEBO; TRIACYLGLYCEROL; DIMINAZENE; ENZYME INHIBITOR; PROTEIN P21; TRANSCRIPTOME;

ACC GENE; ADIPOGENESIS; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CHOLESTEROL BLOOD LEVEL; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; EPIDIDYMIS; FAS MRNA GENE; GENE; GENE EXPRESSION REGULATION; GLUCOSE TOLERANCE; INSULIN SENSITIVITY; LIPID STORAGE; LIPOGENESIS; MALE; METABOLIC REGULATION; MOUSE; NONHUMAN; RETROPERITONEUM; TRANSCRIPTION REGULATION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; BODY WEIGHT; DRUG EFFECTS; HUMAN; METABOLISM;

MUS;

ADIPOSE TISSUE; ANIMALS; BODY WEIGHT; DIMINAZENE; ENZYME INHIBITORS; HUMANS; LIPOGENESIS; MALE; MICE; PEPTIDYL-DIPEPTIDASE A; PROTO-ONCOGENE PROTEINS P21(RAS); TRANSCRIPTOME;

EID: 84931267196     PISSN: 09298665     EISSN: 18755305     Source Type: Journal    
DOI: 10.2174/0929866522666150209125401     Document Type: Article

References (59)

1. Nakazone, M. A.; Pinheiro, A.; Braile, M. C.; Pinhel, M. A.; de Sousa, G. F.; Pinheiro, S., Jr.; Brandao, A. C.; Toledo, J. C.; Braile, D. M.; Souza, D. R. [Prevalence of metabolic syndrome using NCEP-ATPIII and IDF definitions in Brazilian individuals]. Rev. Assoc. Med. Bras., 2007, 53(5), 407-13.
2. Grundy, S. M.; Brewer, H. B., Jr.; Cleeman, J. I.; Smith, S. C., Jr.; Lenfant, C.; American Heart, A.; National Heart, L.; Blood, I. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation, 2004, 109(3), 433-8.
3. Davidson, M. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. Am. J. Cardiol., 2008, 102(12A), 19L-27L.
4. Jones, P. H. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond lowdensity lipoprotein cholesterol lowering. Am. J. Cardiol., 2008, 102(12A), 41L-47L.
5. Nagata, K.; Hattori, T. Cardioprotective mechanisms of lifestyle modifications and pharmacotherapies on cardiac remodeling and dysfunction in hypertensive heart disease: an overview. Nagoya J. Med. Sci., 2011, 73(3-4), 91-105.
6. Singh, B. M.; Mehta, J. L. Interactions between the reninangiotensin system and dyslipidemia: relevance in the therapy of hypertension and coronary heart disease. Arch. Intern. Med., 2003, 163(11), 1296-304.
7. Ueno, N.; Satou, Y. The enhanced effect of atenolol on hypertension in metabolic syndrome. Metab. Syndr. Relat. Disord., 2011, 9(5), 369-73.
8. Xu, Y.; Bao, Q.; He, B.; Pan, Y.; Zhang, R.; Mao, X.; Tang, Z.; Qu, L.; Zhu, C.; Tian, F.; Wang, S. Association of angiotensin I converting enzyme, angiotensin II type 1 receptor and angiotensin I converting enzyme 2 gene polymorphisms with the dyslipidemia in type 2 diabetic patients of Chinese Han origin. J. Endocrinol. Invest., 2012, 35(4), 378-83.
9. Santos, S. H.; Braga, J. F.; Mario, E. G.; Porto, L. C.; Rodrigues- Machado Mda, G.; Murari, A.; Botion, L. M.; Alenina, N.; Bader, M.; Santos, R. A. Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1-7). Arterioscler. Thromb. Vasc. Biol., 2010, 30(5), 953-61.
10. Santos, S. H.; Fernandes, L. R.; Mario, E. G.; Ferreira, A. V.; Porto, L. C.; Alvarez-Leite, J. I.; Botion, L. M.; Bader, M.; Alenina, N.; Santos, R. A. Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes, 2008, 57(2), 340-7.
11. Santos, C. F.; Santos, S. H.; Ferreira, A. V.; Botion, L. M.; Santos, R. A.; Campagnole-Santos, M. J. Association of an oral formulation of angiotensin-(1-7) with atenolol improves lipid metabolism in hypertensive rats. Peptides, 2013, 43, 155-9.
12. Santos, S. H.; Fernandes, L. R.; Pereira, C. S.; Guimaraes, A. L.; de Paula, A. M.; Campagnole-Santos, M. J.; Alvarez-Leite, J. I.; Bader, M.; Santos, R. A. Increased circulating angiotensin-(1-7) protects white adipose tissue against development of a proinflammatory state stimulated by a high-fat diet. Regul. Pept., 2012, 178(1-3), 64-70.
13. Bilman, V.; Mares-Guia, L.; Nadu, A. P.; Bader, M.; Campagnole- Santos, M. J.; Santos, R. A.; Santos, S. H. Decreased hepatic glu- coneogenesis in transgenic rats with increased circulating angiotensin-( 1-7). Peptides, 2012, 37(2), 247-51.
14. Zhu, Y. C.; Zhu, Y. Z.; Lu, N.; Wang, M. J.; Wang, Y. X.; Yao, T. Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and cardiac remodelling. Clin. Exp. Pharmacol. Physiol., 2003, 30(12), 911-8.
15. Welches, W. R.; Brosnihan, K. B.; Ferrario, C. M. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci., 1993, 52(18), 1461-80.
16. Rice, G. I.; Thomas, D. A.; Grant, P. J.; Turner, A. J.; Hooper, N. M. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem. J., 2004, 383(Pt 1), 45-51.
17. Poglitsch, M.; Domenig, O.; Schwager, C.; Stranner, S.; Peball, B.; Janzek, E.; Wagner, B.; Jungwirth, H.; Loibner, H.; Schuster, M. Recombinant Expression and Characterization of Human and Murine ACE2: Species-Specific Activation of the Alternative Renin- Angiotensin-System. Int. J. Hypertens., 2012, 2012, 428950.
18. Moreira de Macedo, S.; Guimaraes, T. A.; Feltenberger, J. D.; Sousa Santos, S. H. The role of renin-angiotensin system modulation on treatment and prevention of liver diseases. Peptides, 2014, 62, 189-96.
19. Clarke, N. E.; Turner, A. J. Angiotensin-converting enzyme 2: the first decade. Int. J. Hypertens., 2012, 2012, 307315.
20. Wysocki, J.; Ye, M.; Rodriguez, E.; Gonzalez-Pacheco, F. R.; Barrios, C.; Evora, K.; Schuster, M.; Loibner, H.; Brosnihan, K. B.; Ferrario, C. M.; Penninger, J. M.; Batlle, D. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension, 2010, 55(1), 90-8.
21. Zhong, J.; Basu, R.; Guo, D.; Chow, F. L.; Byrns, S.; Schuster, M.; Loibner, H.; Wang, X. H.; Penninger, J. M.; Kassiri, Z.; Oudit, G. Y. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation, 2010, 122(7), 717-28, 18 p following 728.
22. Ferreira, A. J.; Shenoy, V.; Qi, Y.; Fraga-Silva, R. A.; Santos, R. A.; Katovich, M. J.; Raizada, M. K. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp. Physiol., 2011, 96(3), 287-94.
23. Gwathmey, T. M.; Pendergrass, K. D.; Reid, S. D.; Rose, J. C.; Diz, D. I.; Chappell, M. C. Angiotensin-(1-7)-angiotensinconverting enzyme 2 attenuates reactive oxygen species formation to angiotensin II within the cell nucleus. Hypertension, 2010, 55(1), 166-71.
24. Thomas, M. C.; Pickering, R. J.; Tsorotes, D.; Koitka, A.; Sheehy, K.; Bernardi, S.; Toffoli, B.; Nguyen-Huu, T. P.; Head, G. A.; Fu, Y.; Chin-Dusting, J.; Cooper, M. E.; Tikellis, C. Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ. Res., 2010, 107(7), 888-97.
25. Fraga-Silva, R. A.; Sorg, B. S.; Wankhede, M.; Dedeugd, C.; Jun, J. Y.; Baker, M. B.; Li, Y.; Castellano, R. K.; Katovich, M. J.; Raizada, M. K.; Ferreira, A. J. ACE2 activation promotes antithrombotic activity. Mol. Med., 2010, 16(5-6), 210-5.
26. Murça TM, M. P., Capuruço CA, Santos SH, Melo MB, Santos RA, Shenoy V, Katovich MJ, Raizada MK, Ferreira AJ. Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. Regul. Pept., 2012, 20(117(1-3)), 107-15.
27. Guang, C.; Phillips, R. D.; Jiang, B.; Milani, F. Three key proteases- angiotensin-I-converting enzyme (ACE), ACE2 and renin- within and beyond the renin-angiotensin system. Arch. Cardiovasc. Dis., 2012, 105(6-7), 373-85.
28. Yamamoto, K.; Ohishi, M.; Katsuya, T.; Ito, N.; Ikushima, M.; Kaibe, M.; Tatara, Y.; Shiota, A.; Sugano, S.; Takeda, S.; Rakugi, H.; Ogihara, T. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension, 2006, 47(4), 718-26.
29. Shiota, A.; Yamamoto, K.; Ohishi, M.; Tatara, Y.; Ohnishi, M.; Maekawa, Y.; Iwamoto, Y.; Takeda, M.; Rakugi, H. Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice. Hypertens. Res., 2010, 33 (4), 298-307.
30. Tikellis, C.; Bialkowski, K.; Pete, J.; Sheehy, K.; Su, Q.; Johnston, C.; Cooper, M. E.; Thomas, M. C. ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes, 2008, 57 (4), 1018-25.
31. Santos, R. A.; Simoes e Silva, A. C.; Maric, C.; Silva, D. M.; Machado, R. P.; de Buhr, I.; Heringer-Walther, S.; Pinheiro, S. V.; Lopes, M. T.; Bader, M.; Mendes, E. P.; Lemos, V. S.; Campagnole- Santos, M. J.; Schultheiss, H. P.; Speth, R.; Walther, T. Angiotensin-( 1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U S A, 2003, 100 (14), 8258-63.
32. Qi, Y.; Zhang, J.; Cole-Jeffrey, C. T.; Shenoy, V.; Espejo, A.; Hanna, M.; Song, C.; Pepine, C. J.; Katovich, M. J.; Raizada, M. K. Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology. Hypertension, 2013, 62 (4), 746-52.
33. Foureaux, G.; Nogueira, J. C.; Nogueira, B. S.; Fulgencio, G. O.; Menezes, G. B.; Fernandes, S. O.; Cardoso, V. N.; Fernandes, R. S.; Oliveira, G. P.; Franca, J. R.; Faraco, A. A.; Raizada, M. K.; Ferreira, A. J. Antiglaucomatous effects of the activation of intrinsic Angiotensin-converting enzyme 2. Invest. Ophthalmol. Vis. Sci., 2013, 54 (6), 4296-306.
34. Shenoy, V.; Gjymishka, A.; Jarajapu, Y. P.; Qi, Y.; Afzal, A.; Rigatto, K.; Ferreira, A. J.; Fraga-Silva, R. A.; Kearns, P.; Douglas, J. Y.; Agarwal, D.; Mubarak, K. K.; Bradford, C.; Kennedy, W. R.; Jun, J. Y.; Rathinasabapathy, A.; Bruce, E.; Gupta, D.; Cardounel, A. J.; Mocco, J.; Patel, J. M.; Francis, J.; Grant, M. B.; Katovich, M. J.; Raizada, M. K. Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am. J. Respir. Crit. Care. Med., 2013, 187 (6), 648-57.
35. Mecca, A. P.; Regenhardt, R. W.; O'Connor, T. E.; Joseph, J. P.; Raizada, M. K.; Katovich, M. J.; Sumners, C. Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke. Exp. Physiol., 2011, 96 (10), 1084-96.
36. Griffin, M. J.; Sul, H. S. Insulin regulation of fatty acid synthase gene transcription: roles of USF and SREBP-1c. IUBMB Life, 2004, 56 (10), 595-600.
37. Santos, E. L.; de Picoli Souza, K.; da Silva, E. D.; Batista, E. C.; Martins, P. J.; D'Almeida, V.; Pesquero, J. B. Long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats. Biochem. Pharmacol., 2009, 78 (8), 951-8.
38. Marcus, Y.; Shefer, G.; Sasson, K.; Kohen, F.; Limor, R.; Pappo, O.; Nevo, N.; Biton, I.; Bach, M.; Berkutzki, T.; Fridkin, M.; Benayahu, D.; Shechter, Y.; Stern, N. Angiotensin 1-7 as means to prevent the metabolic syndrome: lessons from the fructose-fed rat model. Diabetes, 2013, 62 (4), 1121-30.
39. Bianchi, A.; Evans, J. L.; Iverson, A. J.; Nordlund, A. C.; Watts, T. D.; Witters, L. A. Identification of an isozymic form of acetyl-CoA carboxylase. J. Biol. Chem., 1990, 265(3), 1502-9.
40. Kim, K. H. Regulation of mammalian acetyl-coenzyme A carboxylase. Annu. Rev. Nutr., 1997, 17, 77-99.
41. Tong, L. Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug discovery. Cell. Mol. Life Sci., 2005, 62 (16), 1784-803.
42. Kim, T. S.; Leahy, P.; Freake, H. C. Promoter usage determines tissue specific responsiveness of the rat acetyl-CoA carboxylase gene. Biochem. Biophys. Res. Commun., 1996, 225 (2), 647-53.
43. Mario, E. G.; Santos, S. H.; Ferreira, A. V.; Bader, M.; Santos, R. A.; Botion, L. M. Angiotensin-(1-7) Mas-receptor deficiency decreases peroxisome proliferator-activated receptor gamma expression in adipocytes. Peptides, 2012, 33 (1), 174-7.
44. Feltenberger, J. D.; Andrade, J. M.; Paraiso, A.; Barros, L. O.; Filho, A. B.; Sinisterra, R. D.; Sousa, F. B.; Guimaraes, A. L.; de Paula, A. M.; Campagnole-Santos, M. J.; Qureshi, M.; dos Santos, R. A.; Santos, S. H. Oral formulation of angiotensin-(1-7) improves lipid metabolism and prevents high-fat diet-induced hepatic steatosis and inflammation in mice. Hypertension, 2013, 62(2), 324-30.
45. Ayala, J. E.; Samuel, V. T.; Morton, G. J.; Obici, S.; Croniger, C. M.; Shulman, G. I.; Wasserman, D. H.; McGuinness, O. P.; Consortium, N. I. H. M. M. P. C. Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis. Model Mech., 2010, 3(9-10), 525-34.
46. White, P. A. S.; Cercato, L. M.; Araújo, J. M. D.; Souza, L. A.; Soares, A. F.; Barbosa, A. P. O.; R. Neto, J. M. d.; Marçal, A. C.; Machado, U. F.; Camargo, E. A.; Santos, M. R. V.; Brito, L. C. Modelo de obesidade induzida por dieta hiperlipídica e associada à resistência à ação da insulina e intolerância à glicose. Arq. Bras. Endocrinol. Metab., 2013, 57, 339-345.
47. Baur, J. A.; Pearson, K. J.; Price, N. L.; Jamieson, H. A.; Lerin, C.; Kalra, A.; Prabhu, V. V.; Allard, J. S.; Lopez-Lluch, G.; Lewis, K.; Pistell, P. J.; Poosala, S.; Becker, K. G.; Boss, O.; Gwinn, D.; Wang, M.; Ramaswamy, S.; Fishbein, K. W.; Spencer, R. G.; Lakatta, E. G.; Le Couteur, D.; Shaw, R. J.; Navas, P.; Puigserver, P.; Ingram, D. K.; de Cabo, R.; Sinclair, D. A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 2006, 444(7117), 337-42.
48. Oh, Y. B.; Kim, J. H.; Park, B. M.; Park, B. H.; Kim, S. H. Captopril intake decreases body weight gain via angiotensin-(1-7). Peptides, 2012, 37(1), 79-85.
49. Strazzullo, P.; Galletti, F. Impact of the renin-angiotensin system on lipid and carbohydrate metabolism. Curr Opin. Nephrol. Hypertens., 2004, 13(3), 325-32.
50. Engeli, S.; Schling, P.; Gorzelniak, K.; Boschmann, M.; Janke, J.; Ailhaud, G.; Teboul, M.; Massiera, F.; Sharma, A. M. The adiposetissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int. J. Biochem. Cell. Biol., 2003, 35(6), 807-25.
51. Moon, J. Y.; Jeong, K. H.; Lee, S. H.; Lee, T. W.; Ihm, C. G.; Lim, S. J. Renal ACE and ACE2 expression in early diabetic rats. Nephron. Exp. Nephrol., 2008, 110(1), e8-e16.
52. Wang, G.; Lai, F. M.; Kwan, B. C.; Lai, K. B.; Chow, K. M.; Li, P. K.; Szeto, C. C. Expression of ACE and ACE2 in patients with hypertensive nephrosclerosis. Kidney Blood Press Res., 2011, 34(3), 141-9.
53. Takeda, M.; Yamamoto, K.; Takemura, Y.; Takeshita, H.; Hongyo, K.; Kawai, T.; Hanasaki-Yamamoto, H.; Oguro, R.; Takami, Y.; Tatara, Y.; Takeya, Y.; Sugimoto, K.; Kamide, K.; Ohishi, M.; Rakugi, H. Loss of ACE2 exaggerates high-calorie diet-induced insulin resistance by reduction of GLUT4 in mice. Diabetes, 2013, 62(1), 223-33.
54. Jones, B. H.; Standridge, M. K.; Moustaid, N. Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology, 1997, 138(4), 1512-9.
55. Massiera, F.; Seydoux, J.; Geloen, A.; Quignard-Boulange, A.; Turban, S.; Saint-Marc, P.; Fukamizu, A.; Negrel, R.; Ailhaud, G.; Teboul, M. Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology, 2001, 142(12), 5220-5.
56. Tabony, A. M.; Yoshida, T.; Galvez, S.; Higashi, Y.; Sukhanov, S.; Chandrasekar, B.; Mitch, W. E.; Delafontaine, P. Angiotensin II upregulates protein phosphatase 2Calpha and inhibits AMPactivated protein kinase signaling and energy balance leading to skeletal muscle wasting. Hypertension, 2011, 58(4), 643-9.
57. Ha, J.; Kim, K. H. Inhibition of fatty acid synthesis by expression of an acetyl-CoA carboxylase-specific ribozyme gene. Proc. Natl. Acad. Sci. U S A, 1994, 91(21), 9951-5.
58. Munday, M. R.; Hemingway, C. J. The regulation of acetyl-CoA carboxylase-a potential target for the action of hypolipidemic agents. Adv. Enzyme Regul., 1999, 39, 205-34.
59. Santos, R. A.; Ferreira, A. J.; Pinheiro, S. V.; Sampaio, W. O.; Touyz, R.; Campagnole-Santos, M. J. Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs. Expert Opin. Investig. Drugs, 2005, 14(8), 1019-31.